SFX by Ex Libris Inc.

Title:	Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Source:	Nature [0028-0836] Shaffer, Sydney yr:2017

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Long, C. "Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA." Science 345.6201 (2014): 1184-1188.
description	2.	Viswanathan, Vasanthi S. "Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway." Nature. 547.7664: 453-457.
description	3.	Perego, M. "A slow-cycling subpopulation of melanoma cells with highly invasive properties." Oncogene 37.3 (2018): 302-312.
description	4.	Baron, M. "A Single-Cell Transcriptomic Map of the Human and Mouse Pancreas Reveals Inter- and Intra-cell Population Structure." Cell Systems 3.4 (2016): 346-3600000.
description	5.	Sun, C. "Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma." Nature 508.7494 (2014): 118-122.
description	6.	Amoasii, L. "Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy." Science 351.6271 (2015): 400-3.
description	7.	"Research Data from University of Texas Southwestern Update Understanding of Muscular Dystrophy (Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA)." Genomics & Genetics Weekly (2014): 139-.
description	8.	Hangauer, Matthew J. "Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition." Nature 551.7679 (2017): 247-250.
description	9.	"GPX4 Blocks Ferroptosis to Drive the Survival of Chemoresistant Cells." Cancer discovery. 7.9.
description	10.	Yang, W. "Regulation of Ferroptotic Cancer Cell Death by GPX4." Cell 156.1 (2014): 317-331.
description	11.	Loebel, David A F A. "Genomic imprinting: mice without a father." Nature 428.6985 (2004): 809-811.
description	12.	Aird, D. "Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators." Nature Communications 10.1 (2019): 137-137.
description	13.	Nirschl, Christopher J. "IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment." Cell. 170.1: 127-4294967295.
description	14.	Gurtler, M. "Generation of stem cell-derived β-cells from patients with type 1 diabetes." Nature Communications 7.1 (2016): 11463-11463.
description	15.	Melton, Douglas A. "Applied Developmental Biology: Making Human Pancreatic Beta Cells for Diabetics." Curr Top Dev Biol 117.117 (2016): 65-73.
description	16.	Helin, E. "PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies." Nature 514.7521 (2014): 247-51.
description	17.	Bajrami, I. "Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity." Cancer research 74.1 (2013): 287-97.
description	18.	Kanthala, S. "Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3." Biopolymers 101.6 (2013): 693-702.
description	19.	Roesch, A. "Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells." Cancer cell 23.6 (2013): 811-825.
description	20.	Griessinger, J. "β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells." Cancer cell 18.6 (2010): 606-618.